News

For the fourth quarter ended December 31, 2008, Sangamo reported a consolidated net loss of $2.6 million, or $0.06 per share, against a net loss of $6.7 million,

Pfizer has discontinued a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety

RSDecon, a business of Bracco Diagnostics, and Counter Terrorism Solutions have received approval for the importation and use of RSDL chemical warfare agent skin decontamination lotion from the

Roche has announced that it intends to commence a cash tender offer for all outstanding publicly held shares of Genentech at $86.50 per share. Roche, which currently owns

GE Healthcare and Medipattern confirmed their plans to collaborate by signing a definitive collaboration agreement. Medipattern will leverage technology developed in its Cadenza algorithm platform and extend it

The product, Staccato fentanyl (AZ-003/EN-3284), has completed Phase I clinical testing and will be returned to Alexza. In 2007, Endo licensed exclusive rights to develop and commercialize AZ-003

Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design, medicinal chemistry, assay development, in vitro screening, drug metabolism

In addition, Alexza and Endo Pharmaceuticals have agreed to mutually terminate their development agreement for AZ-003 (Staccato fentanyl), a product development candidate that has completed Phase I clinical

Theragenetics, a personalised medicine diagnostics company which develops tests to improve the treatment of patients with central nervous system (“CNS”) disorders such as schizophrenia and depression.  Under the